UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 11 2025
0mins
Source: TipRanks
UnitedHealth Group Stock Performance: UnitedHealth Group's stock has plummeted over 50% year-to-date due to weak Q1 earnings and a lowered full-year outlook, prompting investors to consider ETFs like Harbor Health Care ETF (MEDI) and T. Rowe Price Health Care ETF (TMED) for diversified exposure.
ETF Details and Ratings: The MEDI ETF has a Strong Buy consensus with a 42.79% upside potential, while the TMED ETF holds a Moderate Buy rating with a 41.31% upside potential; both provide indirect exposure to UNH stock, reducing investment risk.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 181.350
Low
240.00
Averages
266.18
High
310.00
Current: 181.350
Low
240.00
Averages
266.18
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services. The Company also provides pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eaton Merges with Dana, Focuses on AI Data Center Growth
- Significant Deal Value: The merger between Dana and Eaton's Mobility business is valued at $5.1 billion, which not only removes a drag on Eaton's earnings growth but also positions the company to capitalize on higher-margin businesses supporting data center buildout, enhancing overall market competitiveness.
- Enhanced Growth Potential: Post-merger, Eaton's overall valuation will reach approximately $10 billion, and by leveraging both companies' technological strengths in vehicle propulsion systems, it is expected to boost Eaton's organic growth rate, further solidifying its market position in electrical equipment.
- Tax Structure Optimization: The transaction utilizes a Reverse Morris Trust structure, allowing Eaton to avoid substantial corporate taxes that would arise from a direct sale, with an anticipated cash distribution of around $1.1 billion to be used for debt repayment or other growth investments, thereby enhancing financial flexibility.
- Positive Market Reaction: Eaton's stock rose over 4% following the merger announcement, currently trading around $391, with analysts generally viewing this transaction as a catalyst for Eaton to accelerate its focus on core higher-growth, higher-margin Electrical and Aerospace businesses, boosting investor confidence.
See More
U.S. Stocks Rise on Semiconductor Rebound Amid Geopolitical Tensions
- Market Rebound: U.S. stocks rose on Thursday, driven by a rebound in semiconductor stocks, with the Dow Jones Industrial Average gaining approximately 341 points, or 0.67%, while the S&P 500 and Nasdaq Composite increased by 0.38% and 0.52%, respectively, demonstrating market resilience amid geopolitical tensions.
- SpaceX IPO Outlook: Wall Street analysts initiated coverage on SpaceX, with New Street Research assigning a $165 price target and Oppenheimer setting a $190 target, as Jim noted that the IPO is likely to have a significant impact on broader market trading, potentially influencing market dynamics for the next month.
- Honeywell Investor Day: Ahead of its planned breakup into aerospace and automation businesses on June 29, Honeywell held an investor day, where Jim expressed optimism about the long-term value creation potential of the automation segment, arguing that the market is underestimating this opportunity, with a potential upside of 50 points post-restructuring.
- Rapid Stock Review: At the end of the video, Jim highlighted stocks including Oracle, Danaher, and Kontoor Brands, indicating ongoing investor interest and potential investment opportunities in these companies.
See More
TRACE-CPE Study Enhances Antibiotic Resistance Testing
- Research Background: The TRACE-CPE study, a collaboration between Imperial College London and Cepheid, aims to enhance antibiotic resistance detection through rapid molecular screening, set to last two and a half years across two major NHS Trust hospitals in England.
- Rapid Testing Advantage: The new study reduces rapid CPE diagnostic result times from 48 hours to approximately one hour, a significant improvement that is expected to enhance clinical practice and infection control, thereby reducing the risk of transmission within hospitals.
- Economic Impact Assessment: TRACE-CPE will evaluate the cost-effectiveness of rapid screening and its impact on patient experience and system-level outcomes, aiming to provide the NHS with a feasibility basis for implementing rapid diagnostics to optimize resource allocation.
- Policy Guidance: Findings from the study will equip policymakers and hospital leaders with essential evidence to guide the effective deployment of rapid CPE screening across the NHS and other health systems facing the rising threat of drug-resistant infections.
See More
Sirius XM to Replace Masimo in S&P MidCap 400 Index
- Acquisition Impact: Danaher Corp. is set to acquire Masimo for $180 per share, valuing the deal at approximately $9.9 billion including debt, with completion expected in the second half of 2026, allowing Masimo to operate as a standalone business within Danaher's Diagnostics segment.
- Index Change: S&P Dow Jones Indices announced that Sirius XM will replace Masimo in the S&P MidCap 400 effective June 11, which is anticipated to trigger buying from index-tracking funds and ETFs, further enhancing Sirius XM's market performance.
- Market Reaction: Sirius XM's market capitalization is around $9 billion, and its shares rose 5% in after-hours trading on Monday, reflecting positive market sentiment regarding its inclusion in the mid-cap index, despite retail investor sentiment remaining bearish.
- Year-to-Date Performance: Sirius XM's stock has gained 34% this year, driven by Berkshire Hathaway's increasing stake and a significant audio advertising partnership with YouTube, indicating the company's ongoing growth potential in the audio entertainment sector.
See More
Sirius XM to Replace Masimo in S&P MidCap 400 Index
- Index Change: Sirius XM Holdings will replace Masimo Corp. in the S&P MidCap 400 Index effective June 11, 2026, which is expected to enhance Sirius XM's visibility in the capital markets and boost investor confidence.
- Acquisition Dynamics: Danaher Corp. is acquiring Masimo, with the deal expected to close soon, which may impact Masimo's market performance and its standing in the healthcare sector.
- Market Impact: Adjustments to the S&P MidCap 400 Index typically prompt investors to reassess their positions, and Sirius XM's inclusion may attract more capital inflow, potentially enhancing its stock performance.
- Industry Outlook: As the largest index provider globally, changes by S&P Dow Jones Indices reflect market confidence in a company's future growth potential, and Sirius XM's inclusion signifies further recognition in the communication services sector.
See More
Sirius XM to Replace Masimo in S&P MidCap 400 Index
- Index Change: Sirius XM Holdings Inc. will replace Masimo Corp. in the S&P MidCap 400 effective June 11, 2026, enhancing Sirius XM's market visibility and investment appeal.
- Acquisition Context: Danaher Corp. is acquiring Masimo, with the deal expected to close soon, leading to Masimo's deletion from the MidCap 400, reflecting ongoing market consolidation in the healthcare sector.
- Market Impact: The inclusion of Sirius XM may attract more investor attention, particularly in the communication services sector, potentially driving up its stock price and strengthening its competitive position.
- Industry Trends: This change not only highlights S&P Dow Jones Indices' responsiveness to market dynamics but also underscores the significance of mid-cap companies in the capital markets, possibly motivating other firms to aim for similar index inclusion.
See More
Eaton Merges with Dana, Focuses on AI Data Center Growth
- Significant Deal Value: The merger between Dana and Eaton's Mobility business is valued at $5.1 billion, which not only removes a drag on Eaton's earnings growth but also positions the company to capitalize on higher-margin businesses supporting data center buildout, enhancing overall market competitiveness.
- Enhanced Growth Potential: Post-merger, Eaton's overall valuation will reach approximately $10 billion, and by leveraging both companies' technological strengths in vehicle propulsion systems, it is expected to boost Eaton's organic growth rate, further solidifying its market position in electrical equipment.
- Tax Structure Optimization: The transaction utilizes a Reverse Morris Trust structure, allowing Eaton to avoid substantial corporate taxes that would arise from a direct sale, with an anticipated cash distribution of around $1.1 billion to be used for debt repayment or other growth investments, thereby enhancing financial flexibility.
- Positive Market Reaction: Eaton's stock rose over 4% following the merger announcement, currently trading around $391, with analysts generally viewing this transaction as a catalyst for Eaton to accelerate its focus on core higher-growth, higher-margin Electrical and Aerospace businesses, boosting investor confidence.
See More
U.S. Stocks Rise on Semiconductor Rebound Amid Geopolitical Tensions
- Market Rebound: U.S. stocks rose on Thursday, driven by a rebound in semiconductor stocks, with the Dow Jones Industrial Average gaining approximately 341 points, or 0.67%, while the S&P 500 and Nasdaq Composite increased by 0.38% and 0.52%, respectively, demonstrating market resilience amid geopolitical tensions.
- SpaceX IPO Outlook: Wall Street analysts initiated coverage on SpaceX, with New Street Research assigning a $165 price target and Oppenheimer setting a $190 target, as Jim noted that the IPO is likely to have a significant impact on broader market trading, potentially influencing market dynamics for the next month.
- Honeywell Investor Day: Ahead of its planned breakup into aerospace and automation businesses on June 29, Honeywell held an investor day, where Jim expressed optimism about the long-term value creation potential of the automation segment, arguing that the market is underestimating this opportunity, with a potential upside of 50 points post-restructuring.
- Rapid Stock Review: At the end of the video, Jim highlighted stocks including Oracle, Danaher, and Kontoor Brands, indicating ongoing investor interest and potential investment opportunities in these companies.
See More
TRACE-CPE Study Enhances Antibiotic Resistance Testing
- Research Background: The TRACE-CPE study, a collaboration between Imperial College London and Cepheid, aims to enhance antibiotic resistance detection through rapid molecular screening, set to last two and a half years across two major NHS Trust hospitals in England.
- Rapid Testing Advantage: The new study reduces rapid CPE diagnostic result times from 48 hours to approximately one hour, a significant improvement that is expected to enhance clinical practice and infection control, thereby reducing the risk of transmission within hospitals.
- Economic Impact Assessment: TRACE-CPE will evaluate the cost-effectiveness of rapid screening and its impact on patient experience and system-level outcomes, aiming to provide the NHS with a feasibility basis for implementing rapid diagnostics to optimize resource allocation.
- Policy Guidance: Findings from the study will equip policymakers and hospital leaders with essential evidence to guide the effective deployment of rapid CPE screening across the NHS and other health systems facing the rising threat of drug-resistant infections.
See More
Sirius XM to Replace Masimo in S&P MidCap 400 Index
- Acquisition Impact: Danaher Corp. is set to acquire Masimo for $180 per share, valuing the deal at approximately $9.9 billion including debt, with completion expected in the second half of 2026, allowing Masimo to operate as a standalone business within Danaher's Diagnostics segment.
- Index Change: S&P Dow Jones Indices announced that Sirius XM will replace Masimo in the S&P MidCap 400 effective June 11, which is anticipated to trigger buying from index-tracking funds and ETFs, further enhancing Sirius XM's market performance.
- Market Reaction: Sirius XM's market capitalization is around $9 billion, and its shares rose 5% in after-hours trading on Monday, reflecting positive market sentiment regarding its inclusion in the mid-cap index, despite retail investor sentiment remaining bearish.
- Year-to-Date Performance: Sirius XM's stock has gained 34% this year, driven by Berkshire Hathaway's increasing stake and a significant audio advertising partnership with YouTube, indicating the company's ongoing growth potential in the audio entertainment sector.
See More
Sirius XM to Replace Masimo in S&P MidCap 400 Index
- Index Change: Sirius XM Holdings will replace Masimo Corp. in the S&P MidCap 400 Index effective June 11, 2026, which is expected to enhance Sirius XM's visibility in the capital markets and boost investor confidence.
- Acquisition Dynamics: Danaher Corp. is acquiring Masimo, with the deal expected to close soon, which may impact Masimo's market performance and its standing in the healthcare sector.
- Market Impact: Adjustments to the S&P MidCap 400 Index typically prompt investors to reassess their positions, and Sirius XM's inclusion may attract more capital inflow, potentially enhancing its stock performance.
- Industry Outlook: As the largest index provider globally, changes by S&P Dow Jones Indices reflect market confidence in a company's future growth potential, and Sirius XM's inclusion signifies further recognition in the communication services sector.
See More
Sirius XM to Replace Masimo in S&P MidCap 400 Index
- Index Change: Sirius XM Holdings Inc. will replace Masimo Corp. in the S&P MidCap 400 effective June 11, 2026, enhancing Sirius XM's market visibility and investment appeal.
- Acquisition Context: Danaher Corp. is acquiring Masimo, with the deal expected to close soon, leading to Masimo's deletion from the MidCap 400, reflecting ongoing market consolidation in the healthcare sector.
- Market Impact: The inclusion of Sirius XM may attract more investor attention, particularly in the communication services sector, potentially driving up its stock price and strengthening its competitive position.
- Industry Trends: This change not only highlights S&P Dow Jones Indices' responsiveness to market dynamics but also underscores the significance of mid-cap companies in the capital markets, possibly motivating other firms to aim for similar index inclusion.
See More
